Recent studies have highlighted the critical role of intrinsic chromatin regulators within tumor cells in shaping the immune tumor microenvironment (TIME) (e.g., EZH2, SETDB1, and ASF1A).[3, 4, 5] Moreover, the inhibition of epigenetic regulators such as SETDB1, KDM5B, and PHF8 has recently been linked to heightened responsiveness to immunotherapy.[6, 7, 8] These findings suggest that integrating epigenetic therapies could potentially augment the effectiveness of ICB therapy, presenting a promising avenue for cancer treatment. Here, ASF1A is linked to neoplasm.